Market Scope

Weekly Ophthalmic News Update – the latest news & trends you need to know: UK Regulators Approve Outlook Therapeutics, Inc.’s #Lytenava (Bevacizumab) for Wet AMD: https://bit.ly/3LkU9m6 Ophthalmic Devices to be Included in FDA TAP Program: https://bit.ly/3S3zGGg US FDA Approves VABYSMOⓇ (faricimab-svoa) Prefilled Syringe for Wet AMD, DME, RVO: https://bit.ly/3S8lsUe Genentech to Reintroduce #Susvimo for Wet AMD, Ending Voluntary Recall: https://bit.ly/3zG5oTr Ophthalmology Chain CLINICA BAVIERA Enters UK Market with Acquisition of Optimax Eye Surgery Specialists: https://bit.ly/4f0ixad Altos Biologics Files for European Approval of Aflibercept (#Eylea) Biosimilar: https://bit.ly/3LuYdA1 China’s DP Technology Will Advance Oral Lp-PLA2 Inhibitor for DR and DME: https://bit.ly/4f4xWGE Alkeus Pharmaceuticals, Inc. Appoints Michel Dahan as President and CEO: https://bit.ly/3xYXBji Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma

Key trends shaping the ophthalmic market in China during the next five years include regulation, an aging population, technological innovation, improving access to diagnosis and treatment, changes in insurance reimbursement policies, rising health care costs, and providers’ ongoing efforts to improve the efficiency of eye care services. A wild card is how much rising nationalism around the globe will affect trade and market access. Market Scope expects the above trends to produce an increase in ophthalmic surgeries, from slightly over 12 million in 2024 to nearly 16 million in 2029, at an average annual growth rate of 5.4 percent. Market Scope's newly published “2024 China Ophthalmic Market Report” covers all aspects of China’s ophthalmic market, providing a comprehensive overview of the Chinese population and economic conditions, discussing key strategic issues, studying disease prevalence, and analyzing surgical and therapeutic approaches, including both commercialized and pipeline products. The report analyzes unit demand and revenue, and forecasts future performance over the next five years. Competitor share is analyzed by product category and 32 competitors are profiled, with discussion of their products, strategic market position, background, and outlook. For more information about this report or to request a sample, please visit https://bit.ly/MS24China or email matthew@market-scope.com. #China #Ophthalmology #Ophthalmic #Market #MarketData #ProcedureVolumes #Cataract #Refractive #Retina #Glaucoma #Cornea #Oculoplasty

Market Scope is pleased to announce the appointment of Kristen Harmon Ingenito, MBA as Chief Executive Officer. David Harmon, the founder of Market Scope, will serve as Chief Financial Officer and Data Security Officer. “I am honored and excited to lead Market Scope and build upon the foundation laid by Dave over the past 28 years,” said Ingenito. “I am extremely proud of the team we have built, and I am excited about this opportunity to further elevate our industry-leading offerings and best support our industry and physician partners.” Kristen Harmon Ingenito brings over two decades of strategic leadership, industry expertise, and a proven track record of driving growth and innovation to her new role as CEO. Ingenito has been with Market Scope for nearly 20 years, most recently serving as the Vice President and Director of Ophthalmics, which involved her managing and guiding the development of all of Market Scope’s over 40 comprehensive market reports. “Kristen’s passion for ophthalmology and innovation and her dedication to our core values make her the ideal candidate to lead Market Scope into its next phase of growth and development,” Harmon said. “Kristen has been unofficially serving in this capacity for some time, and this appointment cements her well-deserved role as the leader of Market Scope.” Read more about this exciting milestone for Market Scope: https://bit.ly/MSKHI For more information about Market Scope and our portfolio of syndicated and primary research services, please visit market-scope.com or contact Matthew Douty at matthewdouty@market-scope.com. #Opthalmology #Appointment #Leadership #Innovation

Weekly Ophthalmic News Update – the latest news & trends you need to know: IOP-Lowering Goggles Developed by John Berdahl, MD, Gain De Novo Nod for Marketing: https://bit.ly/3Wg6YDp US FDA Approves Aflibercept (Eylea) Biosimilar from Formycon AG, Klinge Pharma: https://bit.ly/3xNXx5I Johnson & Johnson Leads Series A Round for Crosslinking Tech Developer TECLens: https://bit.ly/3RZLzNr Roche’s #Vabysmo Gains Positive CHMP Opinion in EU for Third Indication—#RVO: https://bit.ly/3LgsDGj Blinking Boosts Visual Perception Rather than Hindering It, Study Shows: https://bit.ly/3xVXNQ4 US FDA Grants Breakthrough, Regenerative Medicine Status to Aurion Biotech’s Corneal Cell Therapy Candidate: https://bit.ly/3LApAsR Kane Biotech Inc. Licenses Biofilm Dispersion Enzyme to I-MED Pharma Inc. for Dry Eye: https://bit.ly/3We2YEA RevOpsis Therapeutics Enlists India’s Kemwell Biopharma to Manufacture Wet AMD Candidate: https://bit.ly/3XPEgLS Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #DryEye #Surgical #Pharma #WetAMD #IOPLowering

Signs of innovation and renewal can be found in all segments of the cataract equipment market, despite evidence that the market has become mature. Innovation looms in next-generation ultrasonic phaco machines and femtosecond cataract lasers, novel hand-held cataract surgical devices, robotics and new less-invasive ways of cataract removal, and efforts to eliminate OR waste to protect the environment. Phaco machines have gotten better and better since they were first used by cataract surgeons over a half a century ago, although the basic technology remains relatively unchanged, as does the procedure itself. This is not to say that important improvements haven’t been made, because machine refinements are added with every platform upgrade. Over the past five decades, the most significant improvements focused on providing more stable flow control of the anterior chamber during phaco and using as little energy as possible to protect the cornea. However, refinements to ultrasonic phaco today are fewer and farther between, leading surgery centers to hold on to the systems for a longer period of time. In Market Scope’s "2024 Annual US Cataract Surgeon Survey", nearly 50 percent of doctors using phaco machines reported that they kept their machines for 10 years, while another 18 percent held on to them for longer. Comparing the 2024 survey results with those of 2020, it’s evident that the life span of a phaco machine is growing, which slows phaco machine sales. A decade ago, Market Scope estimated the average replacement age of a phaco at about five years. While ultrasonic phaco technology has become safer and more effective, it is far from perfect, and opportunities for improvement still exist. Today, cataract surgeons complain about the cost of machines and the excessive amount of disposable waste created, and they still see a need for improved safety. For example, protecting the cornea during phacoemulsification remains a constant challenge, and having to carefully clean and autoclave ultrasonic handpieces is time consuming. The "2024 Annual US Cataract Surgeon Survey" helps market competitors better understand industry dynamics and gain important insights into surgeons’ experiences and preferences, as well as emerging trends. The survey examines PC-IOLs, toric IOLs, extended depth of focus IOLs, correction of astigmatism, femtosecond laser-assisted cataract surgery (FLACS), surgical locations, interest in upcoming technology, equipment use, treatment and management of glaucoma and MIGS devices, and much more. For more information or to request a sample of this report, please visit https://lnkd.in/gKarsvnD or email matthew@market-scope.com. #Cataract #Surgery #Phaco #USP #FLACS #MarketIntelligence #MarketData #ProductLifespan #PurchasePlan

Weekly Ophthalmic News Update – the latest news & trends you need to know: Alcon Gains US FDA 510(k) Clearance for Unity VCS and CS Systems: https://bit.ly/3L8CYEa ANI Pharmaceuticals, Inc. to Acquire Alimera Sciences, Maker of #Iluvien and #Yutiq, for $381 Million: https://bit.ly/3RMagNe Harrow Looks to Relaunch #Triesence in 2024, as Production Testing Continues: https://bit.ly/3RPPImY US FDA Accepts BLA for Neurotech Pharmaceuticals, Inc.’s MacTel Candidate, Grants Priority Review: https://bit.ly/3xJzbdl Vyluma Plans to Resubmit NDA for Low-Dose Atropine for Myopia after Meeting with US FDA: https://bit.ly/4eHyOk5 US FDA Gives Green Light to Trial of 4D Molecular Therapeutics' Gene Therapy Candidate for GA: https://bit.ly/3zqpr8q #CMS Winding Down Funding Program to Address Change Healthcare Cyberattack: https://bit.ly/3W6DKrI Evolution Optiks Limited Receives US FDA 510(k) Clearance for Tele-refactor: https://bit.ly/4btF3p0 Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma

Manufacturers’ revenue from glaucoma pharmaceuticals fell nearly 4 percent in US dollar terms in 2023, mostly due to the strengthening US dollar, which led to reduced dollar revenue in heavily regulated markets where prices in local currencies could not be raised to counter depreciation in those currencies. The loss of market exclusivity for yet another popular branded drug and the introduction of generic versions played a lesser role. Market revenue is expected to grow with units in 2024 without any further appreciation in the US dollar and with stabilization in the market mix of branded and generic drugs. Newer medicines are gaining traction, but not enough in a single year to offset the overall loss of revenue when generic alternatives emerge for a branded drug. Overall growth in the market is relying only on demographics (the growing population of older people with glaucoma) and the spread of glaucoma care in developing nations. The demographic trend can be weakened or offset, however, if people fail to go to a doctor to get diagnosed. Market Scope anticipates manufacturer revenue from glaucoma medicines will total $4.2 billion in 2024 and forecasts that it will climb to $5.2 billion in 2029 for a compound annual growth rate of nearly 5 percent. However, prospects for the market vary considerably based on the level and rate of development in a country or region. The fastest growth in glaucoma pharmaceuticals use is expected in developing and middle-income countries due to rising affluence, better quality care, and better access to care driving improved diagnostics and treatment in those markets. Market Scope estimates that five-year compound average revenue growth rates will range from just over 1.5 percent in Japan to about 8 percent in our Rest of World category. In dollar terms, however, Market Scope expects the greatest growth in the United States and Western Europe. Market Scope's newly published “2024 Glaucoma Pharmaceuticals Market Report” analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2029 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 26 glaucoma pharmaceutical companies are profiled, with discussion of their products, strategic market position, background, and outlook. For more information or to request a sample of this report, please visit https://bit.ly/24GlPh or email matthew@market-scope.com. 

The June edition of Market Scope’s Ophthalmic Market Perspectives newsletter has been published! This edition features curated coverage of Q1-2024 declines in ophthalmic procedures and company revenues; volume-based procurement possibly upending China's IOL market; surgeon and society response to MACs’ new proposed MIGS limits; upcoming innovations that are expected to rejuvenate the cataract surgical equipment market, and the #EBAA2024 meeting in Kansas City. This issue also covers Nordic Pharma launching Lacrifill canalicular gel for dry eye in the United States; Merck acquiring retinal drug developer EyeBio in a deal worth up to $3 billion; EU regulators approving Outlook Therapeutics, Inc.’s Lytenava for wet AMD; SIFI’s Acanthamoeba keratitis eye drop candidate gaining a positive CHMP opinion; BioTissue introducing its shelf-stable CAM360 AmnioGraft for dry eye and other disorders; Eversight partnering with LighTopTech Corp. to improve imaging of eye tissues; and researchers at the University of Missouri-Columbia finding that the COVID-19 virus can cross the blood-retinal barrier. This 36-page issue includes a total of 21 comprehensive news stories and 22 news briefs, highlights 11 clinical trial updates, and identifies three emerging companies pursuing ophthalmic indications—Eyebot, MediThinQ, and BIOPHTA. To subscribe or request a sample, please visit https://bit.ly/MSOMP or email matthew@market-scope.com. #Ophthalmology #Ophthalmic #News #Market #IndustryNews #MeetingCoverage #EmergingCompanies #ClinicalTrials #Acquisitions

Weekly Ophthalmic News Update – the latest news & trends you need to know: MicroSurgical Technology Offers Diamond Knife Subscription Service in Move to Curb Waste: https://bit.ly/3zb6rKQ Opus Genetics, Abu Dhabi to Collaborate on Retinal Gene Therapies in UAE: https://bit.ly/3xnCUgH Low-Dose Aspirin Shows No Effect in Incidence, Progression of #AMD: https://bit.ly/3zcKo6u Apellis Pharmaceuticals Reports Syfovre Preserved Visual Function at 36 Months in Extension Study: https://bit.ly/3XBl7gw HCP Cureblindness Co-Founder Geoff Tabin, MD to Step Down as Board Chair, Remain Active with Charity: https://bit.ly/3xxyGD1 Eversight Partners with LighTopTech Corp. to Improve Imaging of Eye Tissues: https://bit.ly/3xxyHXB Adverum Biotechnologies Appoints Rabia Gurses Ozden, MD, as Chief Medical Officer: https://bit.ly/45HMIPm Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #SurgicalWaste #Sustainability #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma

The United States is by far the largest cataract equipment market in the world in 2024, with revenue approaching $600 million, or nearly one-third of global sales. country also accounts for more than half of global femtosecond laser-assisted cataract surgery (FLACS) revenue. Western Europe’s revenue has come largely from USP products, with only minimal FLACS penetration. Many European surgeons have challenged the claimed clinical superiority of FLACS over USP alone, and ongoing multi-surgeon, multicenter clinical studies have not supported the claim often made by FLACS users of improved safety and effectiveness. USP pack sales are quite a bit smaller in Japan than in other developed countries because pack reuse is common. About half of USP revenue in any developed region of the world comes from disposable phaco packs, so reuse in Japan significantly cuts down on phaco revenue. There has also been minimal penetration of FLACS lasers in Japan, in large part because of the very small private-pay sector. Countries in our Other Wealthy Nations (OWN) category—such as Canada, Australia, South Korea, Taiwan, and Saudi Arabia— represent the third-largest market, with 2024 cataract equipment revenue of nearly $224 million, or 12 percent of the global total. USP is the dominant cataract removal procedure in each of these countries, and disposable packs are used in a high percentage of cataract surgeries. China is currently a relatively small but emerging market for phaco machines and FLACS lasers. Its market size has been limited by a shortage of ophthalmologists capable of performing phacoemulsification and a lack of health care funds.  India represents a relatively small market for cataract equipment for several reasons—most notably because most cataracts there are still removed using manual small-incision surgery, which does not require a phacoemulsifier, due to the high cost of USP. Most cataracts are also rock hard because of their maturity, making ultrasonic phaco a more challenging procedure. Market Scope expects strong cataract equipment growth in India over the next five years, with revenue growing at a compound annual rate of over 6 percent. Latin America is also a rapidly expanding market for phaco machines, as it continues a steady conversion from extracapsular surgery to ultrasonic phaco. Market Scope's newly published “2024 Cataract Surgical Equipment Market Report” provides in-depth analysis of the global cataract surgical equipment market, examining the market’s size and growth, as well as identifying important developments that may shape its future. The analysis focuses on the 2024 market and forecasts growth and evolution through 2029. Product demand is forecast in units and dollars, and market shares are analyzed by product category. For more information or to request a sample of this report, please visit https://bit.ly/23CSEMR or email matthew@market-scope.com. #CataractSurgery #Phaco #USP #FLACS #Femtosecond #Ophthalmology